Rick Hansen wrote...
> Hello,
>
> I am very interested in finding out more information on the current status of
> the research being done with GPI-1046 by Guilford Pharmaceuticals of
> Baltimore, Maryland and Amgen. Does anyone know of someone who may be
> involved in the clinical trials for this drug? The trials on human subjects
> were scheduled to start the latter part of this year.
>
> Thank you,
>
> Rick Hansen

Hi Rick and all,
I looked up GPI-1046 using the free WebFerret and found a lot
of very interesting background reading... (Scroll to the bottom
for latest info on trials...)

I believe GPI stands for Guilford Pharmaceuticals Inc.

Raw Nerve
OHSU researcher Bruce Gold took what might be the first step in reversing paralysis.
So why is someone else walking away with the glory and the money?
http://www.wweek.com/html/covera052098.html

Bruce Gold
http://www.ohsu.edu/som-CellBio/faculty/gold.html

Research Results of Guilford's Neuroimmunophilin Ligands
Published in Proceedings of the National Academy of Sciences
Tuesday, March 04, 1997
http://pages.prodigy.com/A/L/D/ALSPROD/prodtran.htm

Pill Stimulates CNS Neurons' Regrowth
Psychiatric Times April 1997
http://www.mhsource.com/pt/p970401a.html

New drug may reverse symptoms of Parkinson's  April 9, 1997
http://www.cnn.com/HEALTH/9704/09/nfm/parkinsons/

On April 10, 1997, the Executive Director of NPF,
Mr. Emilio Alonso-Mendoza was interviewed by various
news services regarding the recent announcement of a
drug, GPI-1046, which could possibly reverse
Parkinson's disease.
http://www.parkinson.org/cureqna.htm

A drug now in development could benefit those with
Parkinson's disease, according to scientists who
presented their findings April 15th. 1997 at the
American Chemical Society meeting in San Francisco.
http://www.sd-pc.com/gpi1046.html

Neuroimmunophilin Ligands  August 21, 1997
http://www.heskco.com/karan/pages/newbna.htm

Guilford Reports Brain Cell Regeneration
Date: Wed, 24 Sep 1997
http://web.missouri.edu/~psycmm/abnormal/msg00208.html

Small Molecule Neurotrophins: NI October 1997
http://www.neuroinv.com/neurotrophins.html

Parkinson's Disease Research Treatments GPI-1046
Sheraton Midway Hotel; April 26, 1998
http://www.clinical-services.med.umn.edu/movement-disorders/tuite-talk.htm

Guildford Pharmaceuticals Announces 2nd. Quarter Results
Thu, 16 Jul 98
http://www.iii.co.uk/newsfeed/98/07/16/RESULTS_Guilford-002.shtml

Guilford Pharmaceuticals Inc · 10-K · For 12/31/98
http://www.secinfo.com/dsvRq.61Ze.htm

GPI-1046 and compounds similar to it are also being developed as growth factors to help patients
with PD. It is possible that this treatment will be studied in research trials in humans in 1999 or
2000 to see if it can restore function in PD.
http://www.clinical-services.med.umn.edu/movement-disorders/park3.htm

What is GPI-1046?  Can it possibly reverse Parkinson's disease?
March 1999
http://www.parkinsonsmi.org/newsletter/faqs/experts.html

GPI-1046: Promise of Reversing Parkinson’s  March 24th. 1999
http://www.nwpf.org/news/item990324a.html

Society for Neuroscience 29th Annual Meeting
23-28 October 1999, Miami Beach, FL, USA
GPI-1046
http://www.current-drugs.com/NEWS/NEUROR1.htm

GPI-1046 This compound has the unique property that it can regenerate
dead neurons in the brain
http://www.indobuzz.com/pdfi/news3.htm

Neuroimmunophilin Publications
Abstracts from 1999 Society for Neuroscience
http://www.guilfordpharm.com/b_p_neuro_i.htm

A still-unnamed compound, GPI-1046, developed by the California-based
biotech firm Amgen, has just begun testing in humans. In animal models,
GPI stimulated cells to repair damage in the substantia nigra.
"There is hope that this compound could treat the basic degenerative
process itself," says Lieberman.  Nov. 23, 1999
http://www.usatoday.com/life/health/doctor/lhdoc037.htm

Solomon H. Snyder
http://ww2.med.jhu.edu/pharmacology/pages/faculty/snyder.html

GPI-1046, The First Oral Drug to Stimulate Re-Growth
of Damaged Dopamine Nerve Cells in an Animal Model
of Parkinson Disease January 7th. 2000
By Abraham Lieberman from press releases
of Guilford Pharmaceuticals and Amgen.
http://www.parkinson.org/texthtms/tamgen.htm

April 2000  Cell growth stimulators - GPI-1046, still so new it doesn't have
a trade name, stimulates cell growth in the substantia nigra, a small area
of the midbrain critical to the production of dopamine. The newer NIL-A,
"offers more promise," says Bornstein.
http://www.usatoday.com/life/health/doctor/lhdoc135.htm

May 2, 2000—
GPI-1046, The First Oral Drug to Stimulate Re-Growth of Damaged Dopamine
Nerve Cells in an Animal Model of Parkinson Disease
http://www.nwpf.org/news/item20000508a.html
http://www.egroups.com/message/nwpf-update/79

Winter T, Zimmermann M, Bürger E, Eickmeier C, Herdegen T.
The immunophilin-ligand FK506, but not GPI-1046, protects against neuronal death
and inhibits c-Jun expression in substantia nigra pars compacta following transection
of the rat medial forebrain bundle.
Neuroscience 2000;95:753-762.
http://www.uni-kiel.de/Pharmakologie/publikat.htm

Neuroimmunophilin Ligands – Parkinson’s Disease
Guilford has partnered the neuroimmunophilin program for nerve regeneration in neurological
disorders with Amgen, Inc. Amgen is responsible for all clinical trials. This program includes the
prototype compound GPI-1046 and the clinical lead compound, NIL-A. The initial disease target is
Parkinson’s disease.  Amgen has completed Phase I testing and Guilford anticipates that Phase II
development will proceed in Parkinson’s patients in the second half of 2000.

For more information on this program, or to enquire about enrolling in a clinical study, please
contact Amgen at 1-800-772-6436.

If you are calling from outside the United States, please call (805) 447-1954.
http://www.guilfordpharm.com/b_patient.htm

I try to make a difference ...... murray
[log in to unmask]

View the Parkinson's Awareness Links at:
http://www.geocities.com/janet313/pienet/wwweb/index.html